1. M1a/M1b esophageal carcinoma: Clinical relevance
Neil A. Christie, MDa, Thomas W. Rice, MDa, Malcolm M. DeCamp, MDa, John R. Goldblum, MDb, David J. Adelstein, MDc, Gregory Zuccaro, MDd, Lisa A. Rybicki, MSe, Eugene H. Blackstone, MDa,e 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 118, Issue 5, Pages (November 1999)
DOI: /S (99)
Copyright © 1999 Mosby, Inc. Terms and Conditions

2. Fig. 1
Survival from presentation to death or last follow-up in patients with M1a (solid line) or M1b (light line) disease. The vertical bars represent 1 standard error of the survival estimates. The numbers in parentheses represent the number traced at 12, 24, and 36 months.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (99) )
Copyright © 1999 Mosby, Inc. Terms and Conditions

3. Fig. 2
Survival from presentation to death or last follow-up in patients with M1a disease stratified by surgical (solid line) versus nonsurgical (light line) therapy. The format is as in Fig 1.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (99) )
Copyright © 1999 Mosby, Inc. Terms and Conditions

4. Fig. 3
Survival from presentation to death or last follow-up in patients stratified without (solid line) or with (light line) chemotherapy and/or radiotherapy. The format is as in Fig 1.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (99) )
Copyright © 1999 Mosby, Inc. Terms and Conditions